Nanogen Pegfilgrastim (Pegcyte) PK/PD Clinical Study in Breast Cancer Patients
Clinical trial NCT03376503 · COMPLETED
Trial details
- NCT number
- NCT03376503
- Sponsor
- Nanogen Pharmaceutical Biotechnology Joint Stock Company
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2016-05-25
- Primary completion
- 2017-10-09
- Enrollment
- 24
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.